CMS-D008 / China Medical System - LARVOL DELTA

CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study (ADA 2026) - "CMS-D008 effectively reduced INHBE mRNA expression and lowered its gene product Activin E protein levels in both humanized INHBE DIO mice and obese cynomolgus macaque models. This target engagement promoted healthy weight loss by reducing fat mass while retaining lean mass."

Late-breaking abstract • Preclinical • Metabolic Disorders • Obesity

Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd.

First-in-human • New P1 trial • Genetic Disorders • Obesity

China Medical System Holdings Limited…is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection ('CMS-D008') received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration ('NMPA') on 4 March 2026 (JCN Newswire) - "The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals."

New trial • Obesity